National and Kapodistrian University of Athens
Μια μελέτη ανάλυσης συσχετισμού ολόκληρου του γονιδιώματος για τον προσδιορισμό μονηρών νουκλεοτιδικών πολυμορφισμών που προδιαθέτουν στην εκδήλωση διαπυητικής ιδρωταδενίτιδας
Abstract
dc:descriptionBackground: The wide use of adalimumab (ADA) in the management of Ηidradenitis Suppurativa (HS) generates two different concerns. The first concern is the cost-efficacy of treatment with ADA, and this was explored in a real-world cohort. The second concern arises from the results of randomized clinical trials that show a wide variation in response to ADA treatment in HS. This varied response could be associated with genetic polymorphisms and this was explored in a prospective multicenter clinical trial. Methods: The study has two parts. On the first part, patients-visits were divided into visits under treatment with agents blocking tumor necrosis factor (anti-TNFs) or other therapies. The cost of exacerbations was calculated. The effectiveness of anti-TNFs was calculated by the containment of exacerbations. The primary endpoint for this part of the study was the cost-savings under anti-TNFs. On the second part patients with moderate to severe HS receiving ADA treatment at least 12 weeks were enrolled and Single nucleotide polymorphisms (SNPs) were analyzed. The primary endpoint of this part of the study was the association between carriage of SNPs in the promoter of TNF gene and their response to ADA. Results: Total containment of exacerbations was found in 25.1% of visits under other therapies and in 63.4% of visits under anti-TNFs, with cost-savings per visit under anti-TNFs of the amount of €178.92. In Hurley II stage, mean annual cost was decreased to €3,264.2 with anti-TNFs from €8,309.6 under other therapies (p: 0.004). HiSCR response after 12 weeks of ADA treatment was 71.8% among carriers of the common GGG haplotype and 50.0% among carriers of minor frequency SNP haplotypes (p: 0.031; OR: 0.39). This significance extends to week 36. Conclusions: Treatment with anti-TNFs reduces significant the cost burden of HS through containment of HS exacerbations. Carriage of at least one minor frequency SNP haplotype of the promoter of the TNF gene is associated with lack of response to ADA treatment.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Argyropoulou, Maria
- Αργυροπούλου, Μαρία
Subjects
dc:subject × 16- Διαπυητική ιδρωταδενίτιδα
- Μονονουκλεοτιδικοί πολυμορφισμοί SNPs
- Ανοσολογία
- Φαρμακοοικονομία
- Αντι-TNF παράγοντες
- Hidradenitis suppurativa
- Single nucleotide polymorphisms, SNPs
- Immunology
- Pharmacoeconomics
- Anti-TNF agents
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Γενική και Εσωτερική ιατρική
- Clinical Medicine
- Medical and Health Sciences
- General and Internal Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59058